Skip to main content
Annals of Medicine and Surgery logoLink to Annals of Medicine and Surgery
letter
. 2026 Apr 14;88(6):3859–3860. doi: 10.1097/MS9.0000000000004985

Microbiome-derived metabolites as novel placental functional markers: predictive role in vasa previa

Hasna Panhwar a, Dost Muhammad Panhwar a, Muhammad Mudasir a, Amrendra kumar Mahato b,*
PMCID: PMC13236321  PMID: 42254258

Vasa previa (VP) is a serious pregnancy complication in which fetal vessels, unprotected by Wharton’s jelly, run across or in proximity to the internal cervical os, which can potentially result in fetal exsanguination in the event of membrane rupture[1].

Microbiome-derived metabolites have been implicated in other pregnancy complications characterized by placental dysfunction, highlighting their potential utility as noninvasive markers of placental health[2]. Alterations in maternal metabolite profiles have been shown to influence trophoblast function, inflammation, and vascular signaling pathways critical to placental development[3].

Metabolites from the microbiome are increasingly recognized as important regulators of immune responses and placental vascular development. Short-chain fatty acids, especially butyrate, support angiogenic signaling, maintain endothelial integrity, and help regulate inflammation at the maternal–fetal interface[4].

Changes in the maternal microbiome can alter metabolite levels, potentially disrupting normal placental vessel development and vascular integrity. These alterations may be associated with abnormal placental vascular development and unusual vascular configurations, including VP.

Studies linking inflammatory imbalance and impaired angiogenesis to placental vascular abnormalities provide biological plausibility[5]. However, a direct association between microbiome-derived metabolites and VP has not yet been established. Further prospective research is needed to evaluate the predictive value of these metabolites as noninvasive indicators of placental function in VP.

This manuscript complies with TITAN Guidelines, 2025, declaring no use of AI[6].

Footnotes

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

Published online 14 April 2026

Contributor Information

Hasna Panhwar, Email: hpanhwar12345@gmail.com.

Dost Muhammad Panhwar, Email: panhwardost9@gmail.com.

Amrendra kumar Mahato, Email: amrendramahato901@gmail.com.

Ethical approval

Not applicable, as the manuscript does not involve original data collection or identifiable patient information.

Consent

Not applicable.

Sources of funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author contributions

Conceptualization, literature review, and drafting of the manuscript: H.P.; data interpretation, literature search, and manuscript writing: D.M.P.; literature review, critical revision, and editing of the manuscript: M.M.; supervision, writing – original manuscripts, final review, guarantor of the work, and approval of the manuscript for submission: A.K.M. All authors contributed to the manuscript and approved the final version.

Conflicts of interest disclosure

None.

Research Registration Unique Identifying Number (UIN)

Not applicable.

Guarantor

Amrendra kumar Mahato.

Provenance and peer review

Not applicable.

Data availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

AI usage

During the preparation of this work, the authors used ChatGPT and Grammarly to rectify grammar and spelling mistakes, check reference suitability, and tighten language. After using these tools, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.

Declaration

We confirm that this submission complies with the TITAN 2025 guidelines, and the completed checklist is attached.

Acknowledgements

Not applicable.

References

  • [1].McMahon C, Laiu S, Oyelese Y, et al. Vasa previa guidelines and their supporting evidence. J Perinat Med 2025;53:411–17. [DOI] [PubMed] [Google Scholar]
  • [2].Meng L, Meng M, Zhang R, et al. Microbiome-producing SCFAs are associated with preterm birth via trophoblast function modulation. MBio 2024;15:e02702–24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [3].Gut microbiota and its metabolites modulate pregnancy outcomes by regulating placental autophagy and ferroptosis. [DOI] [PMC free article] [PubMed]
  • [4].Qin X, Zhang M, Chen S, et al. Short-chain fatty acids in fetal development and metabolism. Trends Mol Med 2025;31:625–39. [DOI] [PubMed] [Google Scholar]
  • [5].Weckman AM, Ngai M, Wright J, et al. The impact of infection in pregnancy on placental vascular development and adverse birth outcomes. Front Microbiol 2019;10:1924. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [6].Agha RA, Mathew G, Rashid R, et al. Transparency in the reporting of artificial intelligence—TITAN Guideline. Prem J Sci 2025;10:100082. [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.


Articles from Annals of Medicine and Surgery are provided here courtesy of Wolters Kluwer Health

RESOURCES